Global Cannabis Applications (CSE:APP), a leading developer of innovative smartphone applications for the cannabis industry, announces the launch of its Citizen Green app on Google Play.
The Citizen Green app provides users the ability to find over 2,000 legal providers of cannabis and Cannabinoid products based on distance and availably. Currently the app is available in the following countries: Austria, Belgium, Netherlands, Spain and Germany. Using a secure login users can search by keyword, favor selected products, find providers on an map, launch phone calls and emails to providers by simply tapping on the screen. Weekly updates of products and providers are automatically uploaded to the Citizen Green app. Users must be of legal age in each region to use the application
“We are pleased to announce the launch of our new cannabis focused Citizen Green app on 420 Vancouver day” states CEO, Brad Moore. “This is the first of many new and innovative applications from the Citizen Green family and it is available immediately on Google Play and targeted to the 300,000+ users of the Company’s Foro, Truth and Opinit apps. The Citizen Green app is a real game changer and will help the Company achieve its near and long-term revenue goals.
About Global Cannabis Applications Corp.
Global Cannabis Applications Corp. (“Global Cannabis”) is a global leader in designing, developing, marketing, and acquiring innovative mobile applications. Used in over 25 countries, Global Cannabis’ apps facilitate the proliferation of digital conversations by like-minded people.. Managed by digital industry experts, Global Cannabis is focused on viral global expansionby providing the best user experience in each target market. Its leading mobile platforms are Citizen Green, a platform dedicated to the digital world of all things cannabis; Foro, a peer-to-peer mobile ecommerce student marketplace; Opinit, an app that enables users to socially share their favourite online sentiment-driven content; and Truth, a one-to-one anonymous messaging app.
For more information about Global Cannabis, visit online at www. http://cannappscorp.com/.com, or review its profile on the SEDAR website (www.sedar.com) and on the Canadian SecuritiesExchange’s website (www.thecse.com).
 
To schedule an interview, please contact:
Bradley Moore
Chief Executive Officer
Telephone: 514.561.9091
Email: bmoore@theforo.com
 
For more information, please contact:
Corporate Communications
Telephone: 1.855.269.9554
Email: info@cannappscorp.com
www.cannappscorp.com
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. The Company has no intention or obligation to update or revise any forward looking statements due to new information or events.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information. The Company has no intention or obligation to update or revise any forward looking statements due to new information or events.
Forward-Looking Information:
This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of Global Cannabis. Forward-looking information is based on certain key expectations and assumptions made by the management of Global Cannabis. Although Global Cannabis believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Global Cannabis can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. Global Cannabis disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Source: cannappscorp.com


Agreement propels development of safe and effective proprietary products and formulations for the emerging psychedelic industry

Optimi Health Corp. (CSE: OPTI) (“Optimi” or the “Company”), developers of a vertically integrated functional mushroom brand focused on the health and wellness sector, is pleased to announce that effective January 4, 2021, it entered into a lab services agreement with Numinus Wellness Inc. (“Numinus“). Recognized as an early leader in developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), Numinus is aiding Optimi’s mission to further the research and development of Canadian-grown psilocybin-producing mushrooms and related product formulations.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to provide shareholders with the following corporate update:

Nextleaf Comments on Financial Results from Q1 Financials

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”) reported its second quarter results for the period ended December 31, 2020. A complete set of financial statements and Management’s Discussion & Analysis has been filed at www.sedar.com. All dollar figures are quoted in Canadian dollars.

The second quarter of FY21, saw continued momentum for the Company despite ongoing pandemic related challenges. Net revenue grew 8% to $745,748 from $689,276 versus the same quarter year ago. The Company also saw significant improvement on its bottom line, reducing its net loss by 50% from ($.956) million to ($.481) million, year over year for the quarter, as a result of improved gross margin and cost management efforts. On December 9, 2020, the company announced the closing of the acquisition of substantially all of the assets of Lexaria Canpharm (“Canpharm“), the cannabis products division of Lexaria Biosciences, resulting in the addition of a new B2B Line of Business.

Keep reading... Show less

Royalty Model Provides Access to Early Stage Licenced U.S. Cannabis Companies and Leverage to High-Margin Revenues

FinCanna Capital Corp. (“FinCanna” or the “Company”) (CSE:CALI), a royalty company for the licensed U.S. cannabis industry, is pleased to provide a corporate update further to its recently announced upsized financing of $2 million

Keep reading... Show less

Significant progress made as Numinus-sponsored PRIME study on psilocybin-assisted psychotherapy for opioid, stimulant and/or alcohol use disorders enters pre-implementation stage

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a company creating an ecosystem of health solutions centered around developing and supporting the safe, evidence-based, accessible use of psychedelic-assisted psychotherapies (PAP), and Syreon Corporation (Syreon), a global contract research organization with expertise in conducting clinical trials across a broad range of diseases, are pleased to share that significant progress has been made in the single-arm, open-label compassionate access 1 trial of Psilocybin-Research Intervention with Motivational Enhancement (PRIME) for substance use disorders. Currently in the development stage, the PRIME study will assess the efficacy and safety of psilocybin-assisted motivational enhancement therapy.

Keep reading... Show less